IBUPROFEN TOPICAL IS UNAPPROVED SAYS USFDA

IBUPROFEN TOPICAL IS UNAPPROVED SAYS USFDA

The U.S. Food and Drug Administration announced that the agency issued warning letters to eight companies marketing unlawful over-the-counter (OTC) topical drug products containing the pain reliever ibuprofen

THERE IS NOT A SINGLE PRODUCT OF IBUPROFEN OINTMENT APPROVED FOR TOPICAL ADMINISTRATION

...

published in: 2015-02-16 08:38:29

SILDENAFIL IN HERBAL MEDICINE

SILDENAFIL IN HERBAL MEDICINE

SFDA would like to draw the attention of citizens and expatriates to the fact that  a non registered, non licensed herbal product called ‘Tiger King”, is being promoted as drug-free sexual booster. SFDA’s Laboratories  results showed that it contained SILDENAFIL, with 10 mg/pill concentration

...

published in: 2015-02-16 08:21:16

ROYAL HONEY ADULTERATED WITH DRUGS

ROYAL HONEY ADULTERATED WITH DRUGS

SFDA would like to warn all consumers about (Royal Honey) product, produced by (ETUMAX) company, which is sold and marketed by Itarat Shops and some street - vendors and unknown parties via Social Networks, wherein it is promoted as a natural product Whereas product contains a pharmaceuticals substance called (TADALAFIL), which is used under doctor prescription and supervision, and claiming that it is a natural product is misleading and not true.

...

published in: 2015-02-15 06:47:05

RIYADH PHARMA AND JANSSEN JOINT VENTURE

RIYADH PHARMA AND JANSSEN JOINT VENTURE

Janssen and Riyadh Pharma, the Belgian Janssen Company, and the Medical and Cosmetic Products Company (Riyadh Pharma) have signed a partnership agreement in Saudi Arabia 

...

published in: 2015-02-12 20:43:36

Microneedles in oral capsules? unbelievable! Amazing!

Microneedles in oral capsules? unbelievable! Amazing!

Researchers at MIT and Massachusetts General Hospital (MGH) have devised a novel drug capsule coated with tiny needles that can inject drugs directly into the lining of the stomach after the capsule is swallowed. In animal studies, the team found that the capsule delivered insulin more efficiently than injection under the skin, and there were no harmful side effects as the capsule passed through the digestive system.

Schoellhammer, Traverso, and their colleagues set out to design a capsule that would serve as a platform for the delivery of a wide range of therapeutics, prevent degradation of the drugs, and inject the payload directly into the lining of the GI tract. Their prototype acrylic capsule, 2 centimeters long and 1 centimeter in diameter, includes a reservoir for the drug and is coated with hollow, stainless steel needles about 5 millimeters long.

...

published in: 2015-02-08 18:47:23

EXPENSIVE DRUGS MEANS MORE BENEFITS ???

EXPENSIVE DRUGS MEANS MORE BENEFITS ???
Does getting an 'expensive' drug affect how much patient benefits?

"Patients' expectations play an important role in the effectiveness of their treatments, and the placebo effect has been well documented, especially in people with Parkinson's disease," said study author Alberto J. Espay, MD, MSc, of the University of Cincinnati in Ohio and a Fellow of the American Academy of Neurology. "We wanted to see if the people's perceptions of the cost of the drug they received would affect the placebo response."

...

published in: 2015-02-07 10:35:57

FDA Approves Rechargeable Device to Treat Obesity

FDA Approves Rechargeable Device to Treat Obesity

The U.S. Food and Drug Administration today approved the Maestro Rechargeable System for certain obese adults, the first weight loss treatment device that targets the nerve pathway between the brain and the stomach that controls feelings of hunger and fullness. The Maestro Rechargeable System, the first FDA-approved obesity device since 2007, is approved to treat patients aged 18 and older who have not been able to lose weight with a weight loss program, and who have a body mass index of 35 to 45 with at least one other obesity-related condition, such as type 2 diabetes.

...

published in: 2015-02-04 06:24:41

Mobile Apps for Continuous Glucose Monitoring of diabetic patients

Mobile Apps for Continuous Glucose Monitoring of diabetic patients

The U.S. Food and Drug Administration today allowed marketing of the first set of mobile medical apps that allow people with diabetes to automatically and securely share data from a continuous glucose monitor (CGM) with other people in real-time using an Apple mobile device such as an iPhone.

The Dexcom Share Direct Secondary Displays system’s data-sharing capability allows caregivers to a person with diabetes to monitor that individual’s blood sugar levels remotely through a legally marketed device that is available on mobile devices. Devices like the Dexcom Share were previously available through open source efforts, but were not in compliance with regulatory requirements. The Dexcom Share system is the first of its kind to offer a legally marketed solution for real-time remote monitoring of a patient’s CGM data.

...

published in: 2015-02-02 18:35:34

Drug-Delivering Contact Lens

Drug-Delivering Contact Lens

Eye drops could become a thing of the past thanks to US researchers' recent progress in the field of contact lens-based drug delivery.

Since the 1960s, it's been envisaged that contact lenses could take over from eye drops but the challenge of controlling drug supply levels has so far not been successfully met. Now, a team made up of MIT (Massachusetts Institute of Technology), Boston Children's Hospital and Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology representatives has moved the world one stage further forward.

Together, they have developed a contact lens able to stream glaucoma treatment drug latanoprost on a long-term basis. The contact lens incorporates FDA-approved materials and, under trial conditions, has shown it can stream latanoprost for 30 days, producing in the aqueous humor drug concentration levels similar to those supplied by a daily drop solution.

...

published in: 2015-02-01 22:12:27

India's CSSK Clot-Busting Drug In Phase II Trials

India's CSSK Clot-Busting Drug In Phase II Trials

Set to become India's first patented biopharmaceutical drug, CSSK (Clot Specific Streptokinase) is entering Phase II clinical trials.

The Indian-developed drug treatment is the result of a partnership between Nostrum Pharmaceuticals and CSIR-IMTECH (the CSIR-Institute of Microbial Technology). Approval to move it to a new round trials involving human patients was granted in mid-February 2014 by the Drugs Controller General of India. These patients will share something in common: all have previously experienced heart attacks.

Scientists say that CSSK represents a low-cost alternative to the present generation of thrombolytic (blood clot-dissolving) drugs. That quality should make it much more readily-deployable across India as a whole, since uptake of the more expensive drugs is currently quite limited.

...

published in: 2015-01-31 18:40:29